The startup develops a medical device that utilizes a flushing therapy to minimize blood loss during open-heart surgery. This technology reduces the incidence of blood-related complications and the necessity for re-operations, enhancing patient recovery and lowering hospital costs.
Funding
$12.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HFounders
Product
Problem
Post-operative complications following open-heart surgery, such as residual blood and clots in the pericardial cavity, lead to significant morbidity and mortality. Current drainage systems, largely unchanged since the 19th century, offer limited insight into a patient's post-operative hemostatic status, potentially leading to unnecessary re-operations and increased hospital costs.
Solution
Haermonics has developed the Laebroides system, an innovative flush-therapy designed to prevent blood-related complications following open-heart surgery. The system continuously flushes and cleans the pericardial space, preventing the accumulation of blood and clots. This provides surgeons with real-time data and insight into the patient's condition, reducing the need for re-operations. The Laebroides system aims to improve patient recovery, enhance the quality of life, and reduce overall hospital and infrastructure costs associated with post-operative complications. Clinical trials have demonstrated a significant reduction in blood loss and zero re-operations in flushed patients.
Target Audience
The primary target audience includes cardiothoracic surgeons and hospital staff seeking to improve post-operative outcomes for open-heart surgery patients, reduce complications, and lower associated healthcare costs.
Features
- Continuous flushing of the pericardial space to prevent blood and clot accumulation
- Real-time monitoring of post-operative blood loss and intra-cavital pressure
- Patented design tested in investigational devices
- Demonstrated reduction in blood loss (59% in clinical trials)
- Zero re-operations observed in randomized clinical trials with flushed patients
- Aims to reduce complications such as atrial fibrillation and the need for blood transfusions